Outlook Therapeutics won FDA approval for LYTENAVA, the first and only ophthalmic bevacizumab cleared for wet age-related macular degeneration. The decision gives the company a key foothold in ophthalmology and adds a new option for nAMD patients.
published
Outlook Therapeutics won FDA approval for LYTENAVA, the first and only ophthalmic bevacizumab cleared for wet age-related macular degeneration. The decision gives the company a key foothold in ophthalmology and adds a new option for nAMD patients.
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.